Overview
Retinalamin is a low-molecular-weight polypeptide preparation derived from the retina of cattle, developed by the St. Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson cytomedine family. It is approved and widely used in Russia and several CIS countries for diabetic retinopathy, age-related macular degeneration, retinitis pigmentosa, central chorioretinal dystrophy, post-traumatic retinal damage, and primary open-angle glaucoma. It is not approved in the United States or European Union.
Retinalamin belongs to the broader class of peptide bioregulators that Khavinson and colleagues describe as 'cytomedines'—tissue-specific peptide complexes hypothesized to restore physiological function in the corresponding organ. The proposed mechanisms include direct neurotrophic support of photoreceptors and retinal pigment epithelium, modulation of cytokine signaling, and antioxidant effects.
Evidence comes predominantly from Russian-language open-label studies and small randomized trials. Western evidence is limited. Despite this, Retinalamin is one of the most frequently prescribed adjunct therapies in ophthalmology within its approved markets.
Quick facts
- Mechanism
- Retina-derived polypeptide complex with neurotrophic and metabolic effects on retinal cells
- Primary use
- Diabetic retinopathy, AMD, retinitis pigmentosa (Russia/CIS)
- Evidence
- limited
- FDA
- Not approved
- Route
- Subconjunctival, parabulbar, or intramuscular injection (5 mg/day)
- Typical results
- Reported improvements in visual acuity, ERG amplitudes, and visual field in Russian trials of diabetic retinopathy and AMD
Chemical information
Retinalamin (Peptide complex) is a bioregulator compound with a molecular weight of ~500 g/mol. Its structural characteristics underpin its biological activity in bioregulation and peptide signaling.
How Retinalamin works
Retinalamin contains low-molecular-weight peptides extracted from bovine retina. Proposed mechanisms include stimulation of retinal cell metabolism, modulation of cytokine and growth-factor signaling in retinal pigment epithelium, antioxidant protection of photoreceptors, and improvement of microcirculation in retinal vasculature.
Animal studies suggest Retinalamin preserves photoreceptor outer segments under ischemic or oxidative stress, reduces apoptosis of retinal neurons, and modulates expression of VEGF and other retinal cytokines.
Clinical reports describe improvements in best-corrected visual acuity, electroretinography amplitudes, and visual field indices in patients with diabetic retinopathy and dry AMD when used as an adjunct to standard care.
As with other Khavinson peptide preparations, the specific active components have not been fully characterized, and standardization between batches and manufacturers may vary. Bovine sourcing raises theoretical concerns about prion and viral contamination, mitigated by approved manufacturing controls.
- Retinal neurotrophic support: Targets photoreceptors and RPE
- Antioxidant: Reduces oxidative damage in animal models
- Cytokine modulation: Influences VEGF and inflammatory signaling
- Microcirculation: Improves retinal blood flow in clinical reports
- Adjunct therapy: Typically combined with anti-VEGF or laser treatment
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Composition | Bovine retinal polypeptides <10 kDa | Heterogeneous active ingredient |
| Standard dose | 5 mg IM, subconjunctival, or parabulbar daily for 5–10 days | Approved Russian regimen |
| Course frequency | Often repeated every 3–6 months | Long-term use is common in chronic retinal disease |
| Half-life | Not formally characterized | Local tissue activity emphasized in periocular routes |
| Metabolism | Proteolytic degradation; renal clearance | No CYP involvement expected |
Dosing & administration
Retinalamin dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for Retinalamin is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Injection-site pain or redness
- • Mild conjunctival irritation with periocular routes
- • Transient blurred vision
- • Headache
- • Rare allergic reactions
Serious / potential risks
- • Hypersensitivity reactions to bovine protein
- • Theoretical prion/viral risk (mitigated by approved sourcing)
- • Periocular hematoma with parabulbar injection
- • Unknown effects with long-term repeated courses
- • Not recommended in pregnancy or lactation
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Anti-VEGF agents (ranibizumab, aflibercept) | Often used adjunctively; no formal interaction data | Coordinate with retinal specialist |
| Antidiabetic agents | No direct interaction | Glycemic control remains primary in diabetic retinopathy |
| Antihypertensives | No direct interaction | Blood pressure control is part of retinal disease management |
| Other cytomedines (Cortexin, Thymalin) | Frequently co-prescribed in Russian practice | No documented interaction |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
Retinalamin is a bioregulator compound with research interest in retinal health, vision, bioregulation. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying bioregulation and peptide signaling
- • Individuals interested in retinal health under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Khavinson VKh, Razumovsky MI, Trofimova SV, et al.. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett (2002). PMID: 12500166
- [2] Maksimov IB, Moshetova LK, Savel'eva GN.. Use of Retinalamin in the treatment of involutional central chorioretinal dystrophy. Vestn Oftalmol (2006). PMID: 16708687
- [3] Trofimova SV, Khavinson VKh.. Effect of peptide bioregulators on the functional activity of the retina in patients with retinitis pigmentosa. Bull Exp Biol Med (2002). doi: 10.1023/A:1015862005770 PMID: 12459857